SCHEMBL3595928

SCHEMBL3595928

Nc1cccc2c1NC(=O)C(N1CCS(=O)(=O)CC1)C2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
CRBN Q96SW2 6/20 0.37
RAB9A P51151 1/20 0.35
DDB1 Q16531 4/20 0.33
TNF P01375 2/20 0.33
IL1B P01584 2/20 0.33
IKZF1 Q13422 2/20 0.33
IKZF3 Q9UKT9 2/20 0.33
TBXA2R P21731 1/20 0.33
BRD4 O60885 1/20 0.32
KMT2A Q03164 2/20 0.32
TSHR P16473 1/20 0.32
MEN1 O00255 1/20 0.32
APEX1 P27695 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3593851 0.87 DRD2 (0.41) DRD2DRD4CRBNRAB9ADDB1
SCHEMBL3601780 0.87 TSHR (0.43) DRD2DRD4CRBNRAB9ADDB1
SCHEMBL3595638 0.85 TSHR (0.46) DRD2DRD4CRBNRAB9ADDB1
SCHEMBL3595927 0.85 DRD2 (0.37) DRD2DRD4CRBNRAB9AKMT2A
SCHEMBL3599721 0.84 DRD2 (0.39) DRD2DRD4CRBNRAB9ADDB1
SCHEMBL3604103 0.84 CRBN (0.41) DRD2DRD4CRBNRAB9ADDB1
SCHEMBL3594130 0.83 POLB (0.39) DRD2DRD4CRBNRAB9ADDB1
SCHEMBL3597120 0.83 ALDH1A1 (0.39) DRD2DRD4CRBNRAB9ADDB1
SCHEMBL3607361 0.82 MEN1 (0.40) DRD2DRD4CRBNRAB9ADDB1
SCHEMBL3594551 0.80 ALDH1A1 (0.37) DRD2DRD4CRBNRAB9ADDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 DRD2 530/4885DRD4 795/4885CRBN 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.